Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome

Objective The European Increlex® Growth Forum Database Registry monitors the effectiveness and safety of recombinant human insulin-like growth factor-1 (rhIGF1; mecasermin, Increlex®) therapy in patients with severe primary IGF1 deficiency (SPIGFD). We present data from patients with and without a reported genetic diagnosis of Laron syndrome (LS). Design Ongoing, open-label, observational registry (NCT00903110). Methods Children and adolescents receiving rhIGF1 therapy from 10 European countries were enrolled in 2008–2017 (n = 242). The treatment-naïve/prepubertal (NPP) cohort (n = 138) was divided into subgroups based on reported genetic diagnosis of LS (n = 21) or non-LS (n = 117). Multivariate analysis of the NPP-non-LS subgroup was conducted to identify factors predictive of growth response (first-year-height standard deviation score (SDS) gain ≥ 0.3). Assessments included change in height and weight over 5 years and adverse events (AEs). Results Height SDS gain from baseline was greater in the NPP-LS than the NPP-non-LS subgroup after 1 years’ treatment (P < 0.05). In the NPP-non-LS subgroup, 56% were responders; young age at baseline was a positive independent predictive factor (P < 0.001). NPP-non-LS-responders and the NPP-LS subgroup had a similar mean age (6.07 years vs 7.00 years) at baseline and height SDS gain in year 1 (0.64 vs 0.70), although NPP-non-LS-responders were taller (P < 0.001) at baseline. BMI SDS changes did not differ across subgroups. Treatment-emergent AEs were experienced by 65.3% of patients; hypoglycaemia was most common. Conclusions In most NPP children with SPIGFD, with or without LS, rhIGF1 therapy promotes linear growth. The safety profile was consistent with previous studies.

• Publication year

  2020

• Venue

  European Journal of Endocrinology

• Publication date

  2020-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1530/eje-20-0325PMID 33434161PMCID 7849377
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Comprehensive Cohort Analysis Comparing Growth and GH Therapy Response in IGF1R Mutation Carriers and SGA Children.

  2020cited by this paper
• The European Increlex® Growth Forum Database (EU-IGFD) Registry: Do Treatment Practices Differ Between European Countries?

  2019cited by this paper
• Treatment of severe primary IGF-1 deficiency using rhIGF-1 preparation - first three years of Polish experience.

  2019cited by this paper
• Phenotypic Features and Response to GH Treatment of Patients With a Molecular Defect of the IGF-1 Receptor.

  2019cited by this paper
• Targeted Resequencing of Putative Growth-Related Genes Using Whole Exome Sequencing in Patients with Severe Primary IGF-I Deficiency

  2017cited by this paper
• Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients-From discovery to treatment.

  2016cited by this paper
• STAT5B deficiency: Impacts on human growth and immunity.

  2016cited by this paper
• Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies

  2015cited by this paper
• Effectiveness and Safety of rhIGF-1 Therapy in Children: The European Increlex® Growth Forum Database Experience

  2015cited by this paper
• Managing the Child with Severe Primary Insulin-Like Growth Factor-1 Deficiency (IGFD): IGFD Diagnosis and Management

  2014cited by this paper
• Emerging treatment options for patients with Laron syndrome

  2014cited by this paper
• Adult and Near-Adult Height in Patients with Severe Insulin-Like Growth Factor-I Deficiency after Long-Term Therapy with Recombinant Human Insulin-Like Growth Factor-I

  2013cited by this paper
• Identification and management of poor response to growth‐promoting therapy in children with short stature

  2012cited by this paper
• A Comparison of Different Definitions of Growth Response in Short Prepubertal Children Treated with Growth Hormone

  2011cited by this paper
• Insulin-Like Growth Factor-I and Insulin-Like Growth Factor Binding Protein-3 Cotreatment versus Insulin-Like Growth Factor-I Alone in Two Brothers with Growth Hormone Insensitivity Syndrome: Effects on Insulin Sensitivity, Body Composition and Linear Growth

  2011cited by this paper
• The current status of IGF-I assays--a 2009 update.

  2010cited by this paper
• Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency

  2009cited by this paper
• Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.

  2007cited by this paper
• Total absence of functional acid labile subunit, resulting in severe insulin-like growth factor deficiency and moderate growth failure.

  2006cited by this paper
• Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003.

  2004cited by this paper
• The essential role of IGF-I: lessons from the long-term study and treatment of children and adults with Laron syndrome.

  1999cited by this paper
• Insulin-like growth factor I improves height in growth hormone insensitivity: two years' results.

  1995cited by this paper
• Genetic pituitary dwarfism with high serum concentation of growth hormone--a new inborn error of metabolism?

  1966cited by this paper

• Insulin-like Growth Factor 1 (IGF-1) in Hair Regeneration: Mechanistic Pathways and Therapeutic Potential

  2025cites this paper
• Near-Adult Height Outcomes in Patients Treated With rhIGF-1 for Severe Growth Failure: Real-World IGFD Registry Data

  2025cites this paper
• Challenges of Access to Treatments: The Case Of Laron Syndrome and the Fight For Social Inclusion

  2024cites this paper
• Characterization of Primary IGF-1 Deficiency in a Cohort of Canadian Children with Short Stature Using a Novel Algorithm Tailored to Electronic Medical Records

  2024cites this paper
• Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry

  2023influential citation
• STAT5b: A master regulator of key biological pathways

  2023cites this paper
• Laron syndrome in South Indian children – A descriptive study

  2023cites this paper
• Challenges in the care of individuals with severe primary insulin-like growth factor-I deficiency (SPIGFD): an international, multi-stakeholder perspective

  2023influential citation
• Spatially segregated defects and IGF1‐responsiveness of hilar and peripheral biliary organoids from a model of Alagille syndrome

  2023cites this paper
• First use of gene therapy to treat growth hormone resistant dwarfism in a mouse model

  2022cites this paper
• Progress on growth promoting therapies other than growth hormone.

  2022cites this paper
• Alterations in Stem Cell Populations in IGF-1 Deficient Pediatric Patients Subjected to Mecasermin (Increlex) Treatment

  2022cites this paper
• Pubertal Timing and Growth Dynamics in Children With Severe Primary IGF-1 Deficiency: Results From the European Increlex® Growth Forum Database Registry

  2022cites this paper
• Endocrinologia e diabete

  2021cites this paper